Aurobindo Pharma Ltd
Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)
- Market Cap ₹ 24,065 Cr.
- Current Price ₹ 411
- High / Low ₹ 730 / 407
- Stock P/E 10.7
- Book Value ₹ 436
- Dividend Yield 2.22 %
- ROCE 12.9 %
- ROE 11.7 %
- Face Value ₹ 1.00
Pros
- Stock is trading at 0.94 times its book value
Cons
- The company has delivered a poor sales growth of 9.49% over past five years.
- Dividend payout has been low at 10.2% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4,368 | 4,615 | 5,842 | 8,089 | 12,103 | 13,772 | 14,910 | 16,463 | 19,564 | 23,099 | 24,775 | 23,455 | 23,787 | |
3,405 | 4,050 | 4,965 | 5,951 | 9,524 | 10,579 | 11,469 | 12,691 | 15,612 | 18,249 | 19,497 | 19,100 | 20,085 | |
Operating Profit | 963 | 565 | 877 | 2,137 | 2,579 | 3,193 | 3,441 | 3,772 | 3,952 | 4,849 | 5,278 | 4,356 | 3,702 |
OPM % | 22% | 12% | 15% | 26% | 21% | 23% | 23% | 23% | 20% | 21% | 21% | 19% | 16% |
61 | -300 | 12 | 18 | 81 | 200 | 115 | 105 | 70 | 166 | 3,195 | 192 | 84 | |
Interest | 65 | 277 | 267 | 310 | 160 | 257 | 67 | 78 | 263 | 305 | 74 | 49 | 65 |
Depreciation | 172 | 201 | 249 | 313 | 333 | 392 | 428 | 558 | 668 | 967 | 1,055 | 1,127 | 1,130 |
Profit before tax | 788 | -213 | 374 | 1,533 | 2,168 | 2,744 | 3,061 | 3,241 | 3,091 | 3,743 | 7,344 | 3,373 | 2,590 |
Tax % | 29% | 42% | 22% | 24% | 28% | 26% | 25% | 25% | 24% | 24% | 27% | 22% | |
Net Profit | 563 | -124 | 291 | 1,169 | 1,571 | 2,024 | 2,301 | 2,423 | 2,364 | 2,844 | 5,334 | 2,647 | 2,111 |
EPS in Rs | 9.68 | -2.12 | 5.05 | 20.12 | 26.98 | 34.61 | 39.29 | 41.36 | 40.36 | 48.56 | 91.05 | 45.20 | 36.03 |
Dividend Payout % | 10% | -24% | 15% | 7% | 8% | 7% | 6% | 6% | 6% | 6% | 4% | 20% |
Compounded Sales Growth | |
---|---|
10 Years: | 18% |
5 Years: | 9% |
3 Years: | 6% |
TTM: | -1% |
Compounded Profit Growth | |
---|---|
10 Years: | 31% |
5 Years: | 3% |
3 Years: | 4% |
TTM: | -29% |
Stock Price CAGR | |
---|---|
10 Years: | 16% |
5 Years: | -7% |
3 Years: | -4% |
1 Year: | -39% |
Return on Equity | |
---|---|
10 Years: | 20% |
5 Years: | 17% |
3 Years: | 16% |
Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
29 | 29 | 29 | 29 | 29 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | |
Reserves | 2,416 | 2,311 | 2,577 | 3,721 | 5,127 | 7,229 | 9,313 | 11,622 | 13,832 | 16,766 | 21,871 | 24,517 | 25,469 |
2,414 | 3,096 | 3,435 | 3,769 | 4,451 | 5,041 | 3,364 | 4,770 | 6,967 | 5,826 | 5,339 | 2,851 | 4,501 | |
1,009 | 798 | 1,232 | 1,970 | 3,303 | 3,568 | 3,464 | 4,492 | 5,414 | 6,113 | 6,147 | 6,211 | 7,138 | |
Total Liabilities | 5,868 | 6,234 | 7,273 | 9,490 | 12,910 | 15,896 | 16,200 | 20,942 | 26,271 | 28,765 | 33,416 | 33,638 | 37,167 |
1,739 | 2,195 | 2,639 | 2,722 | 3,706 | 4,180 | 4,834 | 6,521 | 8,475 | 9,396 | 9,374 | 10,532 | 11,616 | |
CWIP | 657 | 645 | 219 | 310 | 420 | 848 | 1,458 | 1,583 | 1,668 | 1,986 | 3,062 | 3,747 | 3,666 |
Investments | 39 | 39 | 22 | 20 | 20 | 123 | 246 | 312 | 360 | 555 | 591 | 997 | 1,543 |
3,433 | 3,355 | 4,393 | 6,439 | 8,765 | 10,745 | 9,662 | 12,527 | 15,768 | 16,827 | 20,390 | 18,362 | 20,343 | |
Total Assets | 5,868 | 6,234 | 7,273 | 9,490 | 12,910 | 15,896 | 16,200 | 20,942 | 26,271 | 28,765 | 33,416 | 33,638 | 37,167 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
335 | 326 | 275 | 646 | 1,237 | 1,420 | 3,279 | 1,955 | 1,651 | 4,381 | 3,329 | 5,016 | |
-603 | -563 | -246 | -819 | -1,017 | -1,446 | -1,787 | -1,927 | -2,904 | -1,563 | 597 | -3,211 | |
407 | 119 | 108 | 118 | 93 | 365 | -1,915 | 864 | 1,919 | -1,947 | -1,365 | -2,969 | |
Net Cash Flow | 139 | -118 | 137 | -55 | 313 | 340 | -424 | 892 | 666 | 871 | 2,561 | -1,164 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 103 | 98 | 100 | 119 | 107 | 122 | 68 | 68 | 64 | 68 | 52 | 62 |
Inventory Days | 244 | 224 | 235 | 240 | 239 | 240 | 246 | 317 | 304 | 289 | 333 | 272 |
Days Payable | 130 | 96 | 118 | 137 | 136 | 146 | 122 | 128 | 107 | 97 | 103 | 97 |
Cash Conversion Cycle | 217 | 226 | 217 | 222 | 210 | 217 | 191 | 257 | 260 | 260 | 282 | 237 |
Working Capital Days | 134 | 148 | 171 | 162 | 126 | 141 | 122 | 139 | 148 | 120 | 124 | 120 |
ROCE % | 20% | 8% | 11% | 27% | 27% | 27% | 25% | 23% | 18% | 19% | 18% | 13% |
Documents
Announcements
- Board Meeting Intimation for Intimation Of Board Meeting 1d
- Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 25 Jan
- Outcome Of Postal Ballot As Per Regulation 30, 44 And Other Applicable Regulations Of The SEBI (LODR) Regulations, 2015 24 Jan
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
18 Jan - The officials of the Company will be participating in the following investor meeting: Date Time Name of the Investor Type of meeting 19-01-2023 7:30 AM …
- Completion Of US FDA Inspection At Unit I & III Of APL Healthcare Limited 18 Jan
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from nse
-
Financial Year 2010
from bse
Concalls
-
Nov 2022TranscriptPPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021Transcript PPT
-
Aug 2021TranscriptPPT
-
Jun 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020Transcript PPT
-
Jun 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Feb 2020TranscriptPPT
-
Jan 2020Transcript PPT
-
Nov 2019TranscriptPPT
-
Nov 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
Aug 2019Transcript PPT
-
Aug 2019Transcript PPT
-
May 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Mar 2019Transcript PPT
-
Feb 2019Transcript PPT
-
Feb 2019TranscriptPPT
-
Jan 2019Transcript PPT
-
Nov 2018TranscriptPPT
-
Nov 2018Transcript PPT
-
Sep 2018TranscriptPPT
-
Sep 2018TranscriptPPT
-
Aug 2018Transcript PPT
-
Aug 2018Transcript PPT
-
May 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Mar 2018TranscriptPPT
-
Feb 2018Transcript PPT
-
Feb 2018TranscriptPPT
-
Feb 2018TranscriptPPT
-
Jan 2018Transcript PPT
-
Nov 2017TranscriptPPT
-
Nov 2017TranscriptPPT
-
Sep 2017Transcript PPT
-
Aug 2017TranscriptPPT
-
Aug 2017TranscriptPPT
-
Jun 2017TranscriptPPT
-
Jun 2017TranscriptPPT
-
Jun 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Mar 2017Transcript PPT
-
Feb 2017TranscriptPPT
-
Feb 2017TranscriptPPT
-
Nov 2016Transcript PPT
-
Nov 2016TranscriptPPT
-
Sep 2016TranscriptPPT
-
Sep 2016Transcript PPT
-
Aug 2016TranscriptPPT
-
Aug 2016TranscriptPPT
-
Jun 2016Transcript PPT
-
Feb 2016Transcript PPT
Leading Pharmaceutical company [1]
Aurobindo Pharma is India’s second-largest pharma company & Largest generics company in the US (by Rx dispensed). It is also the largest generic company in the US and is amongst the top 10 generic companies in seven out of 11 countries in Europe.[2]The Company is among the top 5 listed pharmaceutical companies in India by FY22 revenues [3]